PMID-36652173 – Relugolix Review in Advanced Prostate Cancer
Shirley M. Relugolix: A Review in Advanced Prostate Cancer. Target Oncol. 2023;18(2):295-302.
Quick Reference
| Property | Value |
|---|---|
| PMID | 36652173 |
| DOI | 10.1007/s11523-022-00944-4 |
| Year | 2023 |
| Journal | Targeted Oncology |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (review) |
| Peptide(s) Studied | Relugolix |
Key Findings
- Relugolix (Orgovyx) achieved sustained castration rates exceeding 90% through 48 weeks in the Phase III HERO trial
- Demonstrated noninferiority to leuprolide injections for testosterone suppression
- Provides rapid testosterone suppression without initial flare
- Oral formulation improves treatment convenience compared to injectable depot GnRH agonists
- Evidence suggests a lower cardiovascular risk profile compared to leuprolide
- Side effects are consistent with testosterone suppression (hot flashes, fatigue, musculoskeletal pain)
- Generally acceptable tolerability throughout treatment
Study Design
Comprehensive narrative review covering the pharmacology, clinical efficacy, and safety of oral relugolix for advanced prostate cancer. Synthesizes data from Phase I-III clinical trials with focus on the pivotal HERO trial.
Limitations
- Narrative review (not systematic), subject to selection bias
- Single-author perspective
- Published before long-term HERO follow-up data were fully available
- Does not address comparative cost-effectiveness
Clinical Relevance
This review provides a concise clinical summary of relugolix's pharmacological profile and clinical evidence base. It highlights the drug's unique position as the first and only oral GnRH receptor antagonist approved for prostate cancer, summarizing its advantages (no flare, rapid onset, fast recovery, oral convenience, potential CV benefit) and practical considerations for clinical implementation.
Related
#research #narrative-review #peptide #sexual-health #evidence-level-V